Cargando…

Adipocytes cause leukemia cell resistance to daunorubicin via oxidative stress response

Adipocytes promote cancer progression and impair treatment, and have been shown to protect acute lymphoblastic leukemia (ALL) cells from chemotherapies. Here we investigate whether this protection is mediated by changes in oxidative stress. Co-culture experiments showed that adipocytes protect ALL c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheng, Xia, Tucci, Jonathan, Parmentier, Jean-Hugues, Ji, Lingyun, Behan, James W., Heisterkamp, Nora, Mittelman, Steven D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341969/ https://www.ncbi.nlm.nih.gov/pubmed/27705905 http://dx.doi.org/10.18632/oncotarget.12246

Ejemplares similares

Adipocyte metabolism of the chemotherapy daunorubicin
por: Mittelman, Steven D., et al.
Publicado: (2018)

Adipocytes Provide Fatty Acids to Acute Lymphoblastic Leukemia Cells
por: Tucci, Jonathan, et al.
Publicado: (2021)

The Role of Adipose Tissue and Obesity in Causing Treatment Resistance of Acute Lymphoblastic Leukemia
por: Sheng, Xia, et al.
Publicado: (2014)

Switch to low-fat diet improves outcome of acute lymphoblastic leukemia in obese mice
por: Tucci, Jonathan, et al.
Publicado: (2018)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia
por: Du, Xin, et al.
Publicado: (2017)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Increased lanosterol turnover: a metabolic burden for daunorubicin-resistant leukemia cells
por: Stäubert, Claudia, et al.
Publicado: (2015)

Self-Assembled Daunorubicin/Epigallocatechin Gallate Nanocomplex for Synergistic Reversal of Chemoresistance in Leukemia
por: Bae, Ki Hyun, et al.
Publicado: (2022)

HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/β-catenin signaling
por: Yang, Shuo, et al.
Publicado: (2019)

Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells
por: Gao, Chao, et al.
Publicado: (2020)

Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia
por: Liu, Fu-rong, et al.
Publicado: (2017)

Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis
por: Cacic, Daniel, et al.
Publicado: (2021)

Casein-Based Nanoparticles: A Potential Tool for the Delivery of Daunorubicin in Acute Lymphocytic Leukemia
por: Zahariev, Nikolay, et al.
Publicado: (2023)

Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil.
por: Sehested, M., et al.
Publicado: (1987)

Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin
por: Wang, Jun, et al.
Publicado: (2011)

Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia
por: Al-Aamri, Hussain Mubarak, et al.
Publicado: (2019)

Liposomal daunorubicin as treatment for Kaposi’s sarcoma
por: Petre, Christin E, et al.
Publicado: (2007)

Interactions of Cisplatin and Daunorubicin at the Chromatin Level
por: Firouzi Niaki, Erfaneh, et al.
Publicado: (2020)

Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles
por: Wang, Jun, et al.
Publicado: (2011)

Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
por: Arwanih, Elly Y, et al.
Publicado: (2022)

Marine Benthic Cyanobacteria Contain Apoptosis-Inducing Activity Synergizing with Daunorubicin to Kill Leukemia Cells, but not Cardiomyocytes
por: Oftedal, Linn, et al.
Publicado: (2010)

Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin
por: Han, Yixiang, et al.
Publicado: (2015)

Targeting Notch-1 positive acute leukemia cells by novel fucose-bound liposomes carrying daunorubicin
por: Ono, Michihiro, et al.
Publicado: (2016)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study
por: Samosir, Sunny Mariana, et al.
Publicado: (2021)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3
por: Tavares, Tássia S., et al.
Publicado: (2020)

BET Inhibition Suppresses S100A8 and S100A9 Expression in Acute Myeloid Leukemia Cells and Synergises with Daunorubicin in Causing Cell Death
por: Stewart, Helen J. S., et al.
Publicado: (2018)

TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt/β-catenin signaling
por: Xiao, Yi, et al.
Publicado: (2020)

Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles
por: Zhu, Yuanyuan, et al.
Publicado: (2023)

DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias
por: Boulanger, Mathias, et al.
Publicado: (2023)

Synthesis and Cytotoxic Evaluation of Arimetamycin A and Its Daunorubicin and Doxorubicin Hybrids
por: Huseman, Eric D., et al.
Publicado: (2021)

Dead or alive? The manipulation of neuronal ensembles and pathways by daunorubicin
por: Bashir, Zafar Iqbal, et al.
Publicado: (2017)

Author Correction: Interactions of Cisplatin and Daunorubicin at the Chromatin Level
por: Firouzi Niaki, Erfaneh, et al.
Publicado: (2020)

A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin
por: Cheng, Jian, et al.
Publicado: (2011)

Magnetic nanoparticle of Fe(3)O(4) and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells
por: Chen, Baoan, et al.
Publicado: (2009)

MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin
por: Bollaert, Emeline, et al.
Publicado: (2021)

Reversal of multidrug resistance by magnetic Fe(3)O(4) nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells
por: Chen, Bao-an, et al.
Publicado: (2010)

LncRNA UCA1 elevates the resistance of human leukemia cells to daunorubicin by the PI3K/AKT pathway via sponging miR-613
por: Yao, Qiying, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nsf9flqosco7it3700rb1u932f